Overall rank by patents
#24,901
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 2 technology areas, active 2020–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).
The verdict
Notal holds 11 US patents across 2 technology areas, rank #24,901 of 50,000 tracked assignees.
Notal Vision Ltd. has been granted 11 US utility patents between 2020 and 2025, placing Notal Vision Ltd. at rank #24,901 across all assignees tracked by PlainPatent. This portfolio spans 2 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.8 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a Foreign Corporation, Notal Vision Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Notal sits between Norgen Biotek Corp. (11 patents, rank #24,897) and Nuix Limited (11 patents, rank #24,905) - the closest US assignees by grant volume. The composite Innovation Score of 35.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2025, with 11 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Notal Vision Ltd.'s 19.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 2 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Notal Vision Ltd. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Norgen Biotek Corp.
11 patents
Northeast Institute of Geography and Agroecology, Chinese Academy of Sciences
11 patents
Northeast Petroleum University
11 patents
Norwood Industries Inc.
11 patents
Novanta Corporation
11 patents
Nuclera Nucleics Ltd.
11 patents
Nuflora International Pty Ltd
11 patents
Nuix Limited
11 patents
Notal Vision Ltd.
11 patents
What this shows Notal holds 11 patents at rank #24,901, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Notal's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
35 Top 49% higher than 51% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 3 | 27.3% |
| 2021 | 1 | 9.1% |
| 2022 | 2 | 18.2% |
| 2023 | 2 | 18.2% |
| 2024 | 2 | 18.2% |
| 2025 | 1 | 9.1% |
Top 2 of 2 technology areas
Overall rank by patents
#24,901
Across all tracked assignees
35.5 out of 100
How to use this portfolio
Notal's 11 grants land it in the top 49% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.